Table 2:
Patients and disease characteristics.
IBD (n=200)
CD (n=157)
UC (n=41)
p-value
Patients’ proportion
100%
78.50%
20.50%
Mean age (years)
48.4 ± 13.9
48.5 ± 14.3
48.7 ± 12.5
0.92
Mean length of disease (years)
17.3 ± 11.6
19.1 ± 12.0
11.3 ± 7.3
<0.01
Mean length of follow up (years)
4.3 ± 1.8
4.4 ± 1.9
5.2 ± 5.9
0.86
Men, n (%)
77 (38.5%)
57 (36.3%)
17 (41.5%)
0.54
≥1 IBD-related intestinal resection, n (%)
69 (34.5%)
65 (41.4%)
3 (7.3%)
<0.01
Treatment, n (%)
5-Aminosalicylate, n (%)
57 (28.5%)
27 (17.3%)
29 (70.7%)
<0.01
Immunomodulator, n (%)
59 (29.5%)
52 (33.1%)
7 (17.1%)
0.05
Biologic agent, n (%)
76 (38.0%)
70 (44.6%)
6 (14.6%)
<0.01
Chronic prednisone, n (%)
3 (1.5%)
3 (1.9%)
0 (0%)
0.86
Corticosteroids in the last year, n (%)
25 (12.5%)
22 (14.0%)
3 (7.3%)
0.25
Access to the provincial register, n (%)
163 (81.5%)
129 (82.2%)
33 (80.4%)
0.80
Mean CED (mSv)
23.1 ± 45.2
27.5 ± 49.5
6.8 ± 14.8
<0.01
Exposed to a CED ≥100 mSv, n (%)
6 (3%)
6 (3.8%)
0 (0%)
0.20
CD, Crohn’s disease. CED, cumulative effective dose. IBD, intestinal bowel disease. mSv, millisievert. UC, ulcerative colitis.
p value between CD and UC.